NetworkNewsBreaks – Delic Holdings Corp.’s (CS
Post# of 135
(Total Views: 206)
Posted On: 04/27/2022 4:36:10 PM
NetworkNewsBreaks – Delic Holdings Corp.’s (CSE: DELC) (OTCQB: DELCF) KWC Committed to Providing Clinically-Backed, Accessible, Affordable Treatments
Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, through its subsidiary and the largest ketamine therapy provider in the United States, Ketamine Wellness Centers (“KWC”), recently announced the expansion of its treatment options to include SPRAVATO(R) nasal spray for adults. The first FDA-approved ekestamine nasal spray for adults, SPRAVATO is made explicitly for treatment-resistant depression (“TRD”) along with the treatment of depressive symptoms in adults with major depressive disorder (“MDD”) with suicidal thoughts or actions. A recent article reads, “While making the announcement, Kevin Nicholson, the CEO of KWC and COO of Delic, noted that the introduction of SPRAVATO underscores KWC’s commitment to providing clinically-backed, accessible, and affordable treatments to patients nationwide. He further pointed out that the company’s dedication to offering the highest quality service available, coupled with its vast network of ketamine clinics, allows it to serve more patients than any other ketamine therapy provider.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, through its subsidiary and the largest ketamine therapy provider in the United States, Ketamine Wellness Centers (“KWC”), recently announced the expansion of its treatment options to include SPRAVATO(R) nasal spray for adults. The first FDA-approved ekestamine nasal spray for adults, SPRAVATO is made explicitly for treatment-resistant depression (“TRD”) along with the treatment of depressive symptoms in adults with major depressive disorder (“MDD”) with suicidal thoughts or actions. A recent article reads, “While making the announcement, Kevin Nicholson, the CEO of KWC and COO of Delic, noted that the introduction of SPRAVATO underscores KWC’s commitment to providing clinically-backed, accessible, and affordable treatments to patients nationwide. He further pointed out that the company’s dedication to offering the highest quality service available, coupled with its vast network of ketamine clinics, allows it to serve more patients than any other ketamine therapy provider.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Delic Holdings Corp (DELCF) Stock Research Links
Scroll down for more posts ▼